EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates in Diagnostic Tools for ILD

Arsal Tharwani iD, Manuel L Ribeiro Neto

Journal of Clinical Medicine · 24.04.2025 · 14 (9) · 2924

DOI: 10.3390/jcm14092924 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.04.2025. Verfasst von Arsal Tharwani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interstitial lung disease (ILD) is a group of diffuse parenchymal disorders, which are diagnosed in many cases by multidisciplinary discussion (MDD). In some cases, diagnosis can be challenging, and the addition of histopathology can increase diagnostic confidence. The tools to obtain a histopathological sample to diagnose ILD are expanding. In this review, we will discuss the various modalities, their sensitivities and specificities, and procedural complication rates. In this review, we conducted a comprehensive review of literature focusing on emerging and established diagnostic tools for ILD. A systematic search of peer-reviewed publications was performed using PubMed with a focus on clinical trials, retrospective and prospective cohort studies, and systematic reviews. The key diagnostic modalities in focus were genomic classifier (GC), transbronchial cryobiopsy (TBLC), surgical lung biopsy (SLB), endobronchial ultrasound cryobiopsy (EBUS-C), genetic testing, and speckled transthoracic echocardiography (STE). Data extracted from these studies focused on diagnostic yield, specificity, sensitivity, and procedural complication rate. Genomic classifier, a gene-based molecular diagnostic tool, has a high specificity for histological usual interstitial pneumonia (UIP). However, in cases of a negative result, it often results in a need for further invasive sampling by TBLC or SLB. TBLC results in a larger histological sample, which can increase diagnostic yield and increase diagnostic confidence at MDD. Recent prospective trials have compared this modality with SLB and found 63–77% interobserver agreement between pathologists. SLB remains the gold standard with diagnostic yields reported to be more than 90%. EBUS-C has shown promising results increasing diagnostic yield in patients with suspected sarcoidosis or lymphoma. All diagnostic modalities have procedural complications with most common being pneumothorax, bleeding and, rarely, death. Advancements in diagnostic tools for interstitial lung disease (ILD) have significantly improved accuracy. Even though surgical lung biopsy remains the gold standard, the alternative modalities are promising and provide a promising yield with a lower procedural risk.

Schlagwörter

Stichwörter der Autor:innen

biopsydiagnosisinterstitial lung diseases

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

ORCID-Profile: Arsal Tharwani

Zitieren

APA

Tharwani, A., & Ribeiro Neto, M. L. (2025). Updates in Diagnostic Tools for ILD. Journal of Clinical Medicine, 14(9), 2924. https://doi.org/10.3390/jcm14092924

Vancouver

Tharwani A, Ribeiro Neto ML. Updates in Diagnostic Tools for ILD. Journal of Clinical Medicine. 2025;14(9):2924. doi:10.3390/jcm14092924

BibTeX
@article{Tharwani2025,
  author = {Tharwani, Arsal and Ribeiro Neto, Manuel L},
  title = {Updates in Diagnostic Tools for ILD},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {2924},
  doi = {10.3390/jcm14092924}
}
Kostenlos starten →